Late Breaking Abstract - IMPACT study — single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: healthcare resource utilization and costs — UK
A. Ismaila (Hamilton, ON, Canada), V. Paly (Philadelphia, PA, United States of America), M. Schroeder (Brentford, United Kingdom), A. Martin (Uxbridge, United Kingdom), J. Li (Boston, MA, United States of America), S. Lettis (Uxbridge, United Kingdom), N. Risebrough (Toronto, ON, Canada)
Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS
Session: COPD: from LABA/ICS to LABA/LAMA/ICS
Session type: Oral Presentation
Number: 2128
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Ismaila (Hamilton, ON, Canada), V. Paly (Philadelphia, PA, United States of America), M. Schroeder (Brentford, United Kingdom), A. Martin (Uxbridge, United Kingdom), J. Li (Boston, MA, United States of America), S. Lettis (Uxbridge, United Kingdom), N. Risebrough (Toronto, ON, Canada). Late Breaking Abstract - IMPACT study — single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: healthcare resource utilization and costs — UK. 2128
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: